Disentangling the Relationship between Lewy bodies and nigral neuronal loss in Parkinson's disease

Journal of Parkinson's Disease

Volumn 1, Issue 3, 2011, Pages 277-286

  Parkkinen, Laura ^a,d   O'Sullivan, Sean S ^b   Collins, Catherine ^a   Petrie, Aviva ^c   Holton, Janice L ^a,b   Revesz, Tamas ^a   Lees, Andrew J ^a,b  

^a Queen Square Brain Bank for Neurological Disorders ^*  (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

synuclein; Duration; Lewy bodies; neuronal loss; Parkinson's disease; substantia nigra

Indexed keywords

ALPHA SYNUCLEIN;

ADULT; AGE; AGED; ARTICLE; BRAAK PARKINSON DISEASE STAGE; BRAIN CORTEX; CELL COUNT; CELL DENSITY; CELL HETEROGENEITY; CELL LOSS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NEURONAL LOSS; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTANTIA NIGRA PARS COMPACTA;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CELL DEATH; FEMALE; HUMANS; LEWY BODIES; MALE; MIDDLE AGED; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84858259953     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11046     Document Type: Article

References (44)

1. GoldbergMS, & Lansbury PT Jr (2000) Is there a cause-andeffect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol, 2, E115-E119.
2. Caughey B, & Lansbury PT (2003) Protofibrils, pores, fibrils and neurodegeneration: Separating the responsible protein aggregates from innocent bystanders. Annu Rev Neurosci, 26, 267-298. (Pubitemid 37064935)
3. Volles MJ, & Lansbury PT Jr (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry, 42, 7871-7878. (Pubitemid 36807703)
4. Kramer ML, & Schulz-Schaeffer WJ (2007) Presynaptic aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci, 27, 1405-1410.
5. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, & Kazantsev AG (2006) Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA, 14, 4246-4251.
6. Olanow CW, Perl DP, DeMartino GN, & McNaught KS (2004) Lewy-body formation is an aggresome-related process: A hypothesis. Lancet Neurol, 3, 496-503. (Pubitemid 38903101)
7. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, & MouradianMM( 2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem, 279, 4625-4631. (Pubitemid 38199054)
8. TerryRD(2000) Do neuronal inclusions kill the cell? J Neural Transm Suppl, 59, 91-93. (Pubitemid 30479410)
9. Ǵomez-Isla T, Growdon WB, McNamara M, Newell K, Ǵomez-Tortosa E, Hedley-Whyte ET, & Hyman BT (1999) Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology, 53, 2003-2009.
10. Parkkinen L, KauppinenT, Pirttil̈aT, Autere JM,&Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol, 57, 82-91. (Pubitemid 40053318)
11. Parkkinen L, Pirttila T, & Alafuzoff I (2008) Applicability of current staging/categorization of synuclein pathology and their clinical relevance. Acta Neuropathol, 115, 399-407.
12. Zaccai J, Brayne C, McKeith I, & Matthews F (2008) Ince PGMRCCognitive Function, Ageing Neuropathology Study, Patterns and stages of synucleinopathy: Relevance in a population-based cohort. Neurology, 70, 1042-1048. (Pubitemid 351451312)
13. MarkesberyWR,Jicha GA, Liu H,&Schmitt FA(2009) Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol, 68, 816-822.
14. Halliday GM, Macdonald V, & Henderson JM (2005) A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain, 128, 2272-2280. (Pubitemid 41407967)
15. da Costa CA, Ancolio K, & Checler F (2000) Wild-type but not Parkinson's disease-related ala-53-Thr mutant alpha synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem, 275, 24065-24069. (Pubitemid 30624697)
16. Lee M, Hyun D, Halliwell B, & Jenner P (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem, 76, 998-1009. (Pubitemid 32167373)
17. Saha AR, Ninkina NN, Hanger DP, Anderton BH, & Davies AM (2000) Induction of neuronal death by alpha-synuclein. Eur J Neurosci, 12, 3073-3077.
18. Gertz HJ, Siegers A, & Kuchinke J (1994) Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. Brain Res, 637, 339-341. (Pubitemid 24061072)
19. Tompkins MM, & Hill WD (1997) Contribution of somal Lewy bodies to neuronal death. Brain Res, 775, 24-29. (Pubitemid 28020485)
20. Braak H, Del Tredici K, R̈ub U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211. (Pubitemid 36007810)
21. Braak H, R̈ub U, Jansen Steur EN, Del Tredici K, & de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology, 64, 1404-1410. (Pubitemid 40570509)
22. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL, 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, & Walker DG (2009) Arizona Parkinson's Disease Consortium, Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117, 613-34.
23. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bj̈orklund A, Widner H, Revesz T, Lindvall O, & Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest hot-to-graft disease propagation. Nat Med, 14, 501-503. (Pubitemid 351655211)
24. Brundin P, Li JY, Holton JL, Lindvall O, & Revesz T (2008) Research in motion: The enigma of Parkinson's disease pathology spread. Nat Rev Neurosci, 9, 741-745.
25. Halliday G, Del Tredici K, & Braak H (2006) Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl, 70, 1-5.
26. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, & Lees AJ (2010) Relationships between age and late progression of Parkinson's disease:Aclinico-pathological study. Brain, 133, 1755-1762.
27. Trojanowski JQ,&ReveszT(2007) NeuropathologyWorking Group on MSA, Proposed neuropathological criteria for the post-mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol, 33, 615-620. (Pubitemid 350076093)
28. DicksonDW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, & Litvan I (2009) Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurol, 8, 1150-1157.
29. Halliday G (2004) Substantia nigra and locus coeruleus. In: The Human Nervous System, Paxinos G, &Mai JK, eds., 2nd edn. Elsevier Academic press London, England, pp. 449-463.
30. Ma SY, Collan Y, R̈oytẗa M, Rinne JO, & Rinne UK (1995) Cell counts in the substantia nigra: A comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol, 21, 10-17.
31. Ma SY, R̈oytẗa M, Rinne JO, Collan Y, & Rinne UK (1995) Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Neuropathol Appl Neurobiol, 21, 341-343.
32. Fearnley JM, & Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain, 114, 2283-2301.
33. Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, Meaume S, Piette F, Hauw JJ, & Duyckaerts C (2006) Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-asscoaited neuronal loss in substantia nigra. Arc Neurol, 63, 584-588.
34. Schulz-Schaeffer WJ (2010) The synaptic pathology of (synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol, 120, 131-143.
35. Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H, & Wakabayashi K (2010) Proteinase K-resistant (synuclein is deposited in presynapses in human Lewy body disease and A53T synuclein transgenic mice. Acta Neuropathol, 120, 145-154.
36. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, & White LR (2004) Parkinsonian signs and substantia nigra neuron density in decedents elders without PD. Ann Neurol, 56, 532-539. (Pubitemid 39319343)
37. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, & Duyckaerts C (2010) A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body cause neuronal death. Neurobiol Aging, 31, 99-103.
38. Mori F, Nishie M, Kakita A, Yoshimoto M, Takahashi H, & Wakabayashi K (2006) Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J Neuropathol Exp Neurol, 65, 808-815. (Pubitemid 44200321)
39. Búee L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, Fernandez-Gomez F, Caillierez R, Grosjean ME, Begard S, Barbot B, Demeyer D, Obriot H, Brion I, Búee-Scherrer V, Maurage CA, Balschun D, D'hooge R, Hamdane M, Blum D, & Sergeant N (2010) From tau phosphorylation to tau aggregation: What about neuronal death? Biochem Soc Trans, 38, 967-972.
40. Pollanen MS, Bergeron C, & Weyer L (1992) Detergentinsoluble cortical Lewy body fibrils share epitopes with neurofilament and tau. J Neurochem, 58, 1953-1961.
41. Morsch R, Simon W, & Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol, 58, 188-197. (Pubitemid 29088942)
42. Selikhova M,Williams DR, Kempster PA, Holton JL, Revesz T, & Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson's disease. Brain, 132, 2947-2957.
43. Halliday G, Hely M, Reid W, & Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol, 115, 409-415.
44. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, & Revesz T (2011) Lewy-and Alzheimertype pathologies in Parkinson's disease dementia: Which is more important? Brain, 134, 1493-1505.